JP2009242409A5 - - Google Patents

Download PDF

Info

Publication number
JP2009242409A5
JP2009242409A5 JP2009136739A JP2009136739A JP2009242409A5 JP 2009242409 A5 JP2009242409 A5 JP 2009242409A5 JP 2009136739 A JP2009136739 A JP 2009136739A JP 2009136739 A JP2009136739 A JP 2009136739A JP 2009242409 A5 JP2009242409 A5 JP 2009242409A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
compound
formula
ome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009136739A
Other languages
English (en)
Japanese (ja)
Other versions
JP5210971B2 (ja
JP2009242409A (ja
Filing date
Publication date
Priority claimed from US09/335,003 external-priority patent/US6326507B1/en
Application filed filed Critical
Publication of JP2009242409A publication Critical patent/JP2009242409A/ja
Publication of JP2009242409A5 publication Critical patent/JP2009242409A5/ja
Application granted granted Critical
Publication of JP5210971B2 publication Critical patent/JP5210971B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2009136739A 1998-06-19 2009-06-05 薬剤組成物及び使用方法 Expired - Lifetime JP5210971B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9005398P 1998-06-19 1998-06-19
US60/090,053 1998-06-19
US09/335,003 US6326507B1 (en) 1998-06-19 1999-06-17 Therapeutic compounds and methods of use
US09/335,003 1999-06-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000554358A Division JP4541548B2 (ja) 1998-06-19 1999-06-18 薬剤組成物及び使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012102499A Division JP2012144574A (ja) 1998-06-19 2012-04-27 薬剤組成物及び使用方法

Publications (3)

Publication Number Publication Date
JP2009242409A JP2009242409A (ja) 2009-10-22
JP2009242409A5 true JP2009242409A5 (US07846941-20101207-C00217.png) 2012-06-14
JP5210971B2 JP5210971B2 (ja) 2013-06-12

Family

ID=22221055

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000554358A Expired - Lifetime JP4541548B2 (ja) 1998-06-19 1999-06-18 薬剤組成物及び使用方法
JP2009136739A Expired - Lifetime JP5210971B2 (ja) 1998-06-19 2009-06-05 薬剤組成物及び使用方法
JP2012102499A Withdrawn JP2012144574A (ja) 1998-06-19 2012-04-27 薬剤組成物及び使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000554358A Expired - Lifetime JP4541548B2 (ja) 1998-06-19 1999-06-18 薬剤組成物及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012102499A Withdrawn JP2012144574A (ja) 1998-06-19 2012-04-27 薬剤組成物及び使用方法

Country Status (10)

Country Link
US (7) US6326507B1 (US07846941-20101207-C00217.png)
EP (2) EP2062577A1 (US07846941-20101207-C00217.png)
JP (3) JP4541548B2 (US07846941-20101207-C00217.png)
AT (1) ATE430563T1 (US07846941-20101207-C00217.png)
CA (1) CA2335505C (US07846941-20101207-C00217.png)
CY (1) CY1109256T1 (US07846941-20101207-C00217.png)
DK (1) DK1089724T3 (US07846941-20101207-C00217.png)
ES (1) ES2324966T3 (US07846941-20101207-C00217.png)
PT (1) PT1089724E (US07846941-20101207-C00217.png)
WO (1) WO1999065478A1 (US07846941-20101207-C00217.png)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080275104A1 (en) * 1997-11-25 2008-11-06 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20040072138A1 (en) * 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
AU3653301A (en) * 2000-01-28 2001-08-07 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
AU2002243246A1 (en) * 2000-11-28 2002-06-24 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
US6777004B1 (en) * 2001-03-30 2004-08-17 Council Of Scientific & Industrial Research Composition containing novel compound corniculatonin having antifungi properties and a process for preparing the same
KR100464063B1 (ko) * 2001-11-21 2005-01-06 한국생명공학연구원 세포사멸 유도작용을 갖는 트리테르펜 화합물
EP1465615B1 (en) * 2002-01-15 2012-08-01 Trustees of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
BR0309754A (pt) * 2002-05-02 2007-03-13 Univ Washington métodos e composições para tratamento de distúrbios e doenças auto-imunes/inflamatórias mediados por célula t em indivìduos tendo uma deficiência de regulação de glicocorticóide
CA2485565A1 (en) * 2002-05-13 2004-08-05 Trustees Of Dartmouth College Inhibitors and methods of use thereof
WO2005034958A1 (en) * 2003-10-10 2005-04-21 Sk Chemicals, Co., Ltd. Triterpene compounds which are effective on improvement of brain function
US20050208151A1 (en) * 2003-10-30 2005-09-22 Entelos, Inc. Treatment of rheumatoid arthritis with FLIP antagonists
US7551346B2 (en) * 2003-11-05 2009-06-23 E Ink Corporation Electro-optic displays, and materials for use therein
JP2007516294A (ja) * 2003-12-23 2007-06-21 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 炎症性の疾患または症状の予防および治療のための方法および組成物
US7638331B2 (en) 2004-01-02 2009-12-29 The Administration of the Tulane Rducation Fund Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
US20080318931A1 (en) * 2004-07-08 2008-12-25 Moshe Arkin Treatment of Disorders and Diseases of the Colon
US8128967B2 (en) * 2005-03-08 2012-03-06 Mitsui Norin Co., Ltd. Polyphenol coxib combinations and methods
US20100190735A1 (en) * 2006-03-28 2010-07-29 Myrex Pharmaceuticals Inc. Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
JP2010510243A (ja) * 2006-11-17 2010-04-02 トラスティーズ オブ ダートマス カレッジ 三環系−ビス−エノン(tbe)の合成および生物学的活性
WO2008064132A2 (en) * 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
WO2008112887A1 (en) * 2007-03-13 2008-09-18 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
US20090048205A1 (en) * 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
US7879369B2 (en) 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
US9012439B2 (en) * 2007-10-29 2015-04-21 University Of Rochester Use of electrophilic compounds for inducing platelet production or maintaining platelet function
RS58486B1 (sr) 2008-01-11 2019-04-30 Reata Pharmaceuticals Inc Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti
ES2326065B1 (es) * 2008-03-28 2010-07-08 Consejo Superior De Investigaciones Cientificas (Csic) Utilizacion de un triterpeno pentaciclico para la preparacion de una composicion farmaceutica destinada al tratamiento de la esclerosis multiple.
CN102164941B (zh) 2008-04-18 2015-05-27 里亚塔医药公司 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物
PL2276493T3 (pl) 2008-04-18 2019-05-31 Reata Pharmaceuticals Inc Antyoksydacyjne modulatory stanu zapalnego: pochodne kwasu oleanolowego z amino- i innymi modyfikacjami przy C-17
BRPI0911422B8 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals Inc compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
CN102066397B (zh) 2008-04-18 2013-09-11 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
AU2009274037B2 (en) * 2008-07-22 2015-07-09 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
KR101483203B1 (ko) 2009-02-13 2015-01-15 리아타 파마슈티컬즈, 아이엔씨. 무정형 cddo-me를 포함하는, 지연 방출형 경구 투여 조성물
WO2010124974A2 (en) * 2009-04-30 2010-11-04 Sanofi-Aventis Deutschland Gmbh Needle remover and method for removing a needle
ME03713B (me) 2010-04-12 2021-01-20 Reata Pharmaceuticals Inc Bardoksolon meтil za lečenje gojaznosтi
KR101220782B1 (ko) 2010-09-14 2013-01-09 제주대학교 산학협력단 신규 트리테르페노이드 및 이의 용도
PL2651902T3 (pl) 2010-12-17 2018-04-30 Reata Pharmaceuticals, Inc. Pirazolilowe i pirymidynylowe tricykliczne enony jako modulatory zapalenia o działaniu przeciwutleniającym
UY33946A (es) 2011-03-11 2012-08-31 Reata Pharmaceuticals Inc Derivados de c4-monometil triterpenoides y sus métodos de uso
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
PT2841445T (pt) 2012-04-27 2017-09-01 Reata Pharmaceuticals Inc Derivados de 2,2-difluoropropionamida de metil bardoxolona, formas polimorfas e métodos de uso dos mesmos
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US8791067B2 (en) 2012-07-24 2014-07-29 Morehouse School Of Medicine Method for treating malaria
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
PE20150627A1 (es) 2012-09-10 2015-06-04 Reata Pharmaceuticals Inc Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso
WO2014040056A1 (en) * 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
CA2884400A1 (en) * 2012-09-10 2014-03-13 Abbvie Inc. Glycyrrhetinic acid derivatives and methods of use thereof
CN102887936A (zh) * 2012-10-24 2013-01-23 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
EP2977381B1 (en) 2013-03-19 2018-09-26 Daiichi Sankyo Company, Limited Terpenoid derivative
TW201936625A (zh) 2013-04-24 2019-09-16 美商艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
US9290455B2 (en) 2014-02-11 2016-03-22 Trustees Of Dartmouth College CDDO-Me amino acid conjugates and methods of use
WO2016033132A1 (en) 2014-08-26 2016-03-03 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
US10189791B2 (en) 2014-08-26 2019-01-29 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
CN106661080A (zh) 2014-09-10 2017-05-10 第三共株式会社 用于治疗和预防眼科疾病的缓释药物组合物
JP6748652B2 (ja) 2015-02-12 2020-09-02 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化性炎症調節剤としてのイミダゾリル三環式エノン
EA201890767A1 (ru) 2015-09-23 2019-09-30 Рита Фармасьютикалз, Инк. C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
US10953020B2 (en) 2016-11-08 2021-03-23 Reata Pharmaceuticals, Inc. Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物
US11434190B2 (en) * 2016-12-23 2022-09-06 The University Of Queensland Inhibitors of SOX18 protein activity for treating angiogenesis-and/or lymphangiogenesis-related diseases
WO2019014412A1 (en) 2017-07-13 2019-01-17 Pliva Hrvatska D.O.O. NOVEL CRYSTALLINE POLYMORPHIC FORMS OF METHYL BARDOXOLONE
CN112654610A (zh) 2018-06-15 2021-04-13 里亚塔医药公司 用于抑制IL-17和RORγ的吡唑和咪唑化合物
TW202038918A (zh) 2018-11-27 2020-11-01 日商協和麒麟股份有限公司 醫藥組合物
EP4259155A1 (en) 2020-12-11 2023-10-18 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ191586A (en) * 1978-10-10 1981-10-19 Sterling Drug Inc Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
IL77133A (en) * 1984-12-04 1991-01-31 Lilly Co Eli Antineoplastic pharmaceutical compositions containing pentofuranoside derivatives,some new such compounds and their preparation
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
IL84842A0 (en) 1986-12-24 1988-06-30 Lilly Co Eli Immunoglobulin conjugates
IL89258A0 (en) 1988-02-16 1989-09-10 Lilly Co Eli 2',3'-dideoxy-2',2'-difluoro-nucleosides
US5064823A (en) * 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
CA2004695C (en) 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
AU7558491A (en) 1990-04-04 1991-10-30 Nycomed Imaging As Nucleoside derivatives
WO1992012991A1 (en) 1991-01-29 1992-08-06 Shionogi Seiyaku Kabushiki Kaisha Triterpene derivative
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
YU43193A (sh) 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
US5426183A (en) * 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5606048A (en) 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5401838A (en) * 1992-06-22 1995-03-28 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
UA41261C2 (uk) 1992-06-22 2001-09-17 Елі Ліллі Енд Компані Спосіб одержання збагачених бета-аномером нуклеозидів
DE4308042C2 (de) * 1993-03-13 2000-10-12 Alstom Energy Syst Gmbh Wälzmühle
US6025395A (en) * 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US5972703A (en) * 1994-08-12 1999-10-26 The Regents Of The University Of Michigan Bone precursor cells: compositions and methods
US5521294A (en) * 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
ATE249842T1 (de) 1996-07-03 2003-10-15 Upjohn Co Zielgerichte arzneimittel abgabe für zulphonamide-derivate
PL186888B1 (pl) 1997-01-24 2004-03-31 Conpharma As Pochodne gemcytabiny
US20050276836A1 (en) * 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6485756B1 (en) * 1999-04-06 2002-11-26 Collaborative Technologies, Inc. Stable, homogeneous natural product extracts containing polar and apolar fractions
CA2372962C (en) 1999-05-14 2008-04-08 Nereus Pharmaceuticals, Inc. Novel interleukin-1 and tumor necrosis factor-.alpha. modulators, syntheses of said modulators and methods of using said modulators
CA2341263C (en) 1999-06-25 2006-08-01 Roche Diagnostics Corporation Enzyme inhibition immunoassay
WO2002003996A1 (en) 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
AU2002243246A1 (en) 2000-11-28 2002-06-24 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
HUP0500054A2 (hu) 2001-11-23 2005-04-28 Chugai Seiyaku Kabushiki Kaisha Tumorjelző enzimek azonosítására szolgáló eljárás
EP1465615B1 (en) 2002-01-15 2012-08-01 Trustees of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
CA2485565A1 (en) * 2002-05-13 2004-08-05 Trustees Of Dartmouth College Inhibitors and methods of use thereof
US7265096B2 (en) * 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US20050208151A1 (en) 2003-10-30 2005-09-22 Entelos, Inc. Treatment of rheumatoid arthritis with FLIP antagonists
WO2005046732A2 (en) 2003-11-04 2005-05-26 THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH Methods and compositions for the inhibition of hiv-1 replication
JP5087400B2 (ja) 2004-09-07 2012-12-05 パシフィック アロー リミテッド アンゲロイル基を有する抗腫瘍化合物
WO2007005879A2 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
DE102005041613A1 (de) 2005-09-01 2007-03-08 Ergonex Pharma Gmbh Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom
NZ569078A (en) 2005-12-12 2012-01-12 Mosamedix Bv Annexin derivatives suitable for pretargeting in therapy and diagnosis
WO2008064132A2 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
JP2010510243A (ja) 2006-11-17 2010-04-02 トラスティーズ オブ ダートマス カレッジ 三環系−ビス−エノン(tbe)の合成および生物学的活性
WO2008111497A1 (ja) 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
US20090048205A1 (en) 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
RS58486B1 (sr) 2008-01-11 2019-04-30 Reata Pharmaceuticals Inc Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti
BRPI0911422B8 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals Inc compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
CN102066397B (zh) 2008-04-18 2013-09-11 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
CN102164941B (zh) 2008-04-18 2015-05-27 里亚塔医药公司 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物
PL2276493T3 (pl) 2008-04-18 2019-05-31 Reata Pharmaceuticals Inc Antyoksydacyjne modulatory stanu zapalnego: pochodne kwasu oleanolowego z amino- i innymi modyfikacjami przy C-17
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
AU2009274037B2 (en) 2008-07-22 2015-07-09 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
KR101483203B1 (ko) 2009-02-13 2015-01-15 리아타 파마슈티컬즈, 아이엔씨. 무정형 cddo-me를 포함하는, 지연 방출형 경구 투여 조성물
ME03713B (me) 2010-04-12 2021-01-20 Reata Pharmaceuticals Inc Bardoksolon meтil za lečenje gojaznosтi
UY33946A (es) 2011-03-11 2012-08-31 Reata Pharmaceuticals Inc Derivados de c4-monometil triterpenoides y sus métodos de uso

Similar Documents

Publication Publication Date Title
JP2009242409A5 (US07846941-20101207-C00217.png)
JP2016534063A5 (US07846941-20101207-C00217.png)
JP2016040288A5 (US07846941-20101207-C00217.png)
JP2009502743A5 (US07846941-20101207-C00217.png)
JP7045985B2 (ja) Ezh2阻害剤を用いた髄芽腫の処置方法
JP2009502777A5 (US07846941-20101207-C00217.png)
JP2013510885A5 (US07846941-20101207-C00217.png)
JP2013510120A5 (US07846941-20101207-C00217.png)
JP2013032389A5 (US07846941-20101207-C00217.png)
JP2017511321A5 (US07846941-20101207-C00217.png)
JP2009536191A5 (US07846941-20101207-C00217.png)
JP2013518107A5 (US07846941-20101207-C00217.png)
JP2010138190A5 (US07846941-20101207-C00217.png)
JP2011504903A5 (US07846941-20101207-C00217.png)
JP2012530779A5 (US07846941-20101207-C00217.png)
JP2006514012A5 (US07846941-20101207-C00217.png)
JP2015512943A5 (US07846941-20101207-C00217.png)
JP2017522277A5 (US07846941-20101207-C00217.png)
JP2012532883A5 (US07846941-20101207-C00217.png)
JP2012504560A5 (US07846941-20101207-C00217.png)
JP2010522710A5 (US07846941-20101207-C00217.png)
JP2013533253A5 (US07846941-20101207-C00217.png)
JP2010090149A5 (US07846941-20101207-C00217.png)
JP2013537240A5 (US07846941-20101207-C00217.png)
JP2009502775A5 (US07846941-20101207-C00217.png)